CD19 and neoplasm: Simultaneously administering CD19 CAR-T and CD123 CAR-T cells prevented CD19-loss relapse in B-ALL xenograft models and enhanced the tumor killing efficacy, demonstrating the importance of targeting multiple tumor associated antigens (TAAs) [77].